Elevra Lithium mines spodumene concentrate from its NAL operation in Québec, selling almost entirely into China's lithium chemical supply chain. At A$8.20 against our fair value of A$4.80, the stock is overvalued by 41%. The market is pricing a structural lithium bull market as a near-certainty; we think the odds are closer to a coin flip.

The best fit for ELV is the thematic investor with a long time horizon, high risk tolerance, and genuine conviction on the structural lithium story — someone who believes EV adoption will sustain spodumene prices above US$1,100 per tonne and who views the brownfield expansion as a near-certainty. For that investor, the bull case of A$8.14 roughly matches today's price. Everyone else is paying a premium for optionality that may never be exercised.

Elevra Lithium is a Québec-based spodumene producer, formed by the 2025 merger of Sayona Mining and Piedmont Lithium. It earns revenue by mining lithium-bearing ore at the North American Lithium operation and shipping concentrate to chemical converters, 82% of whom are in China.

The first half of FY26 illustrated both the opportunity and the problem. Revenue reached US$86M as prices recovered 34% from their trough, but true underlying group EBITDA remained negative once a favourable inventory accounting adjustment was stripped out. The company is profitable at the mine level; it is not profitable at the group level.

The investment case rests on two things happening simultaneously: spodumene prices recovering to and sustaining above US$1,000 per tonne, and the planned brownfield expansion reaching a final investment decision. Our analysis assigns 50% probability to the expansion proceeding and weights the cyclical price hypothesis at 55% — meaningfully more cautious than the market's implied view. Eighty per cent of our total enterprise value sits in development assets that do not yet exist. That concentration of value in pre-feasibility optionality is the defining characteristic of this investment.

At A$8.20 versus our fair value of A$4.80, the stock is overvalued by 41%.

What happened?

The first half of FY26 was a study in the distance between appearances and reality. Spodumene prices recovered to US$937 per tonne and reported underlying EBITDA landed at US$0.8M — technically positive. Strip out the US$9.4M non-cash inventory revaluation that management included in that figure, and true group EBITDA was negative US$8.6M. A production downgrade mid-period, driven by ore grade deterioration in a transitional mining zone, compounded the disappointment.

What's next?

The path to profitability runs almost entirely through spodumene pricing. At our base case assumption of US$980 per tonne in FY27, EBITDA turns positive for the first time — but EBIT remains in the red until FY28. Free cash flow doesn't turn positive until FY28 at the earliest.

Two catalysts matter most. First, the H2 FY26 quarterly production report (due April 2026) will reveal whether the ore grade deterioration is temporary or structural — a sustained unit cost above US$900 per tonne would signal a permanent cost problem, not a transitional one. Second, the brownfield expansion feasibility study is expected in the second half of calendar 2026. The scoping study put the project NPV at C$1.28B; the full feasibility study will either validate that number or cut it, as feasibility studies historically do by 20-40%.

No dividend is forecast for the foreseeable future. The company holds US$81M in cash, which provides roughly 18 months of runway at current burn rates.

What could go wrong?

The single biggest risk is a permanent floor in spodumene pricing set by Chinese lepidolite processing. Chinese producers expanded lepidolite capacity by roughly 40% in 2024-25, creating a structural competitor that can produce lithium chemicals at an equivalent spodumene cost of US$700-800 per tonne. If that cost curve proves durable, hard-rock spodumene will struggle to sustain prices above US$900 per tonne — the level at which ELV barely covers its operating costs.

Every US$100 per tonne move in the spodumene price shifts our fair value by approximately A$1.80 per share. That sensitivity dominates every other assumption in the model, including the discount rate, the terminal multiple, and management's ability to cut unit costs. At current pricing, a return to the 2024 trough of US$700 per tonne would render the operating mine essentially worthless and collapse the development pipeline's optionality value — pushing the stock toward our severe downside case of A$0.73.